| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-03-10 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.690 | ||||||
| REV | 0 |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of TCR2 Therapeutics (NASDAQ: TCRR) through any online brokerage.
Other companies in TCR2 Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), AVEO Pharmaceuticals (NASDAQ:AVEO), Alzamend Neuro (NASDAQ:ALZN), Orchard Therapeutics (NASDAQ:ORTX) and Brooklyn (NASDAQ:BTX).
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by Goldman Sachs on January 19, 2022. The analyst firm set a price target for 5.00 expecting TCRR to rise to within 12 months (a possible 58.73% upside). 10 analyst firms have reported ratings in the last year.
The stock price for TCR2 Therapeutics (NASDAQ: TCRR) is $3.15 last updated Today at 9:00:03 PM.
There are no upcoming dividends for TCR2 Therapeutics.
TCR2 Therapeutics’s $Q4 earnings are confirmed for after-market on March 10, 2022.
There is no upcoming split for TCR2 Therapeutics.
TCR2 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.